Form 4: Lemaitre Vascular Director Acquires Dividend Equivalent Rights

Lemaitre Vascular Director Lawrence J. Jasinski reported the acquisition of dividend equivalent rights tied to restricted and performance stock units.

Summary

• Director Lawrence J. Jasinski of Lemaitre Vascular Inc. (LMAT) reported the acquisition of dividend equivalent rights (DERs) on September 4, 2025.
• These DERs are tied to previously granted Restricted Stock Unit (RSU) and Performance Stock Unit (PSU) awards, with each DER being the economic equivalent of one share of the Issuer's common stock.
• The DERs vest proportionately with their respective underlying RSU and PSU awards.
• The transactions were executed under a Rule 10b5-1(c) plan, indicating a pre-arranged trading strategy.
• Specific acquisitions on September 4, 2025, include 0.4173 DERs related to a 12/12/2022 RSU award, 0.4173 DERs from a 12/12/2022 PSU award, 0.7138 DERs from a 12/8/2023 RSU award, 0.8546 DERs from a 12/8/2023 PSU award, and 0.8697 DERs from a 12/6/2024 RSU award.
• Following these transactions, Mr. Jasinski beneficially owns 6.5156, 5.5269, 5.3975, 5.8691, and 2.9094 DERs respectively from these specific awards.

Sentiment

Score: 6

Explanation: The filing reports routine accruals of dividend equivalent rights by a director under a pre-arranged plan. This is a standard compensation practice that aligns insider interests with shareholders and reflects good corporate governance, but it does not contain information that would significantly alter the company's outlook or valuation.

Positives

• The acquisition of dividend equivalent rights by a director increases their beneficial interest in the company, aligning their financial incentives with shareholder returns.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged, systematic approach to insider transactions, which is a positive corporate governance practice.
• The DERs are tied to existing equity awards (RSUs and PSUs), reinforcing the long-term incentive structure for management.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

The use of dividend equivalent rights (DERs) as part of executive compensation is a common practice across various industries, including the medical device sector where Lemaitre Vascular operates. This mechanism helps align the interests of company insiders, such as directors, with those of shareholders by providing them with the economic benefit of dividends on their unvested equity awards. Many publicly traded companies utilize similar equity-based incentive programs to attract, retain, and motivate key personnel.

Comparison to Industry Standards

• The structure of granting dividend equivalent rights alongside restricted stock units (RSUs) and performance stock units (PSUs) is a standard practice in executive compensation across the medical device industry and broader public markets.
• Companies like Medtronic (MDT), Boston Scientific (BSX), and Abbott Laboratories (ABT) frequently employ similar long-term incentive plans that include equity awards and associated dividend equivalents to ensure management's interests are aligned with shareholder value creation.
• The use of Rule 10b5-1(c) plans for these transactions is also a widely accepted corporate governance practice, demonstrating a commitment to transparent and pre-planned insider trading, consistent with industry best practices.

Corporate Governance

Related Party Transactions

• The acquisition of dividend equivalent rights by Director Lawrence J. Jasinski is a related-party transaction, as it involves compensation provided by the company to an insider.
• These transactions are part of the company's established equity compensation plans for its directors and executives.

Stakeholder Impact

• Shareholders: The accrual of dividend equivalent rights by a director aligns their financial interests more closely with those of shareholders, as the value of these rights is tied to the company's common stock and its dividend policy.
• Employees (specifically executives/directors): The transactions reflect the ongoing execution of the company's long-term incentive compensation plans, which are designed to attract and retain key talent.

Next Steps

• Continued vesting of the underlying Restricted Stock Unit (RSU) and Performance Stock Unit (PSU) awards, to which these dividend equivalent rights are proportionately tied.
• Future reporting of changes in beneficial ownership as additional DERs accrue or as underlying equity awards vest and convert to common stock.

Key Dates

Recommendation

This Form 4 reports routine accruals of dividend equivalent rights by a director, which are part of a pre-existing compensation plan. While it indicates continued alignment of insider interests with shareholders, it does not present new information significant enough to alter an investment thesis or warrant a strong buy/sell recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals.

Keywords

Lemaitre Vascular, LMAT, Form 4, Insider Transaction, Dividend Equivalent Rights, Restricted Stock Units, Performance Stock Units, Director Compensation, Equity Awards